Skip to main content Skip to navigation Skip to search

About Us
Technology
Pipeline
News and Media
Investor
Contact

Home
News and Media
Subscribe

News and Media

Press releases
Events
Subscribe
FAQ

Subscribe

Subscribe to our latest financial information

Choose type

Financial reports Press releases

E-mail

Something went wrong - please make sure you entered the correct email.

I consent to Curasight handling my personal data. See Curasight's Terms of Use for information about how we handle personal data.

Thank you. You will get an e-mail message to activate your subscription.

Subscribe

Subscribe to get the latest news first.

Choose type

Financial reports Press releases

E-mail

Something went wrong - please make sure you entered the correct email.

I consent to Curasight handling my personal data. See Curasight's Terms of Use for information about how we handle personal data.

Thank you. You will get an e-mail message to activate your subscription.

Curasight – a Danish biotech company that develops a more gentle and efficient detection and treatment of cancer.

Curasight's team are the pioneers behind the novel uPAR Theranostics technology. The technology minimizes irradiation of healthy tissue by combining the targeted uTREAT® radiation therapy with the precise uTRACE® diagnostics. Several investigator-initiated phase II clinical trials have been completed or are currently undertaken.

News and Media
Contact
Terms of use

Copyright 2024 © Curasight

This website uses cookies to provide the best possible user experience. If you continue without making any changes you allow this. Read more about cookies here